Wellcome Open Research (Mar 2022)

An optimization of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams [version 2; peer review: 2 approved]

  • Shadrack Mutua,
  • Brian Bartilol,
  • Shaban J. Mwangi,
  • Debra Riako,
  • Lydia Nyamako,
  • Bonface M. Gichuki,
  • Henry Karanja,
  • Angela Karani,
  • John N. Gitonga,
  • Daisy Mugo,
  • Brian Tawa,
  • Wilson Gumbi,
  • Wesley Cheruiyot,
  • Metrine Tendwa,
  • John K. Nyambu,
  • Yiakon Sein,
  • Thani Suleiman Thani,
  • Shem O. Patta,
  • Benson Kitole,
  • Eric K. Maitha,
  • Barke S. Muslih,
  • Mohamed S. Mwakinangu,
  • Philip Bejon,
  • Benjamin Tsofa,
  • Joyce U. Nyiro,
  • John Ochieng Otieno,
  • Leonard Ndwiga,
  • Patience Kiyuka,
  • Johnstone Makale,
  • Kevin Wamae,
  • Victor Osoti,
  • John Mwita Morobe,
  • Calleb Odundo,
  • Arnold W. Lambisia,
  • Martin Mutunga,
  • Salim Mwarumba,
  • Lynette Isabella Ochola-Oyier,
  • Charles N. Agoti,
  • Clement Lewa,
  • Elijah Gicheru,
  • Jennifer Musyoki,
  • Susan Njuguna,
  • Horace Gumba,
  • Domtila Kimani,
  • Jedidah Mwacharo,
  • Zaydah R. de Laurent,
  • Khadija Said Mohammed,
  • Robinson Cheruiyot,
  • Donwilliams O. Omuoyo

Journal volume & issue
Vol. 5

Abstract

Read online

Background: The COVID-19 pandemic relies on real-time polymerase chain reaction (qRT-PCR) for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), to facilitate roll-out of patient care and infection control measures. There are several qRT-PCR assays with little evidence on their comparability. We report alterations to the developers’ recommendations to sustain the testing capability in a resource-limited setting. Methods: We used a SARS-CoV-2 positive control RNA sample to generate several 10-fold dilution series that were used for optimization and comparison of the performance of the four qRT-PCR assays: i) Charité Berlin primer-probe set, ii) European Virus Archive – GLOBAL (EVAg) primer-probe set, iii) DAAN premixed commercial kit and iv) Beijing Genomics Institute (BGI) premixed commercial kit. We adjusted the manufacturer- and protocol-recommended reaction component volumes for these assays and assessed the impact on cycle threshold (Ct) values. Results: The Berlin and EVAg E gene and RdRp assays reported mean Ct values within range of each other across the different titrations and with less than 5% difference. The DAAN premixed kit produced comparable Ct values across the titrations, while the BGI kit improved in performance following a reduction of the reaction components. Conclusion: We achieved a 2.6-fold and 4-fold increase in the number of tests per kit for the commercial kits and the primer-probe sets, respectively. All the assays had optimal performance when the primers and probes were used at 0.375X, except for the Berlin N gene assay. The DAAN kit was a reliable assay for primary screening of SARS-CoV-2 whereas the BGI kit’s performance was dependent on the volumes and concentrations of both the reaction buffer and enzyme mix. Our recommendation for SARS-CoV-2 diagnostic testing in resource-limited settings is to optimize the assays available to establish the lowest volume and suitable concentration of reagents required to produce valid results.

Keywords